Related Experiment Videos
[The mild encephalitis-hypothesis--new findings and studies].
1Psychiatrie II der Universität Ulm, Bezirkskrankenhaus Günzburg. karl.bechter@bkh-guenzburg.de
Psychiatrische Praxis
|December 1, 2004
Summary
Mild encephalitis (ME), potentially triggered by infections, may underlie psychiatric disorders like schizophrenia. Treatments targeting ME showed promise in improving symptoms of acute schizophrenia and therapy-resistant psychoses.
Area of Science:
- Neuroscience
- Psychiatry
- Immunology
Background:
- The etiology of psychiatric disorders remains largely unknown.
- Infections and subsequent immune responses, termed mild encephalitis (ME), are hypothesized to contribute to neurological and behavioral disturbances.
- Emerging evidence links ME to conditions like schizophrenia, bipolar disorder, and autoimmune disorders.
Purpose of the Study:
- To explore the role of mild encephalitis (ME) in the pathogenesis of psychiatric disorders.
- To investigate the potential of novel therapeutic strategies targeting ME in psychiatric conditions.
Main Methods:
- Review of recent findings in pathology, biochemistry, and neuroimaging related to schizophrenia and bipolar psychoses.
- Analysis of clinical data from patients with Chorea Sydenham and PANDAS syndrome.
- Evaluation of add-on therapies including Cox-II blockers, valacyclovir, and cerebrospinal fluid (CSF) filtration.
Main Results:
- Neuroimaging, biochemical, and pathological findings in schizophrenia and bipolar disorder are consistent with the ME hypothesis.
- Autoimmune ME appears to be a significant factor in the anxiety, compulsive, and hyperactivity symptoms observed in Chorea Sydenham and PANDAS syndrome.
- Add-on therapy with Cox-II blockers or valacyclovir demonstrated improvements in acute schizophrenia.
- CSF filtration showed positive outcomes in some cases of therapy-resistant psychoses.
Conclusions:
- Mild encephalitis (ME) is a plausible contributing factor to the development of psychiatric disorders.
- Targeting ME through therapies like Cox-II blockers, valacyclovir, or CSF filtration may offer new treatment avenues for psychiatric conditions, including therapy-resistant cases.